- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
New Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA
Co-Developed by Janssen Diagnostics, test will help prevent future outbreaks of Ebola
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
SIMPONI Recommended for Sixth Indication in Europe and First in Pediatric Population
U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
In a Phase 3 study of patients not previously treated with any diabetes medication, combination therapy with canagliflozin and metformin lowered blood sugar more than either medicine alone
New Phase 3 Study Findings Show STELARA® Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn’s Disease
Approximately 50 Percent of STELARA®-treated Patients Achieved Clinical Remission According to Pivotal Phase 3 IM-UNITI Study Results Presented for the First Time at Digestive Disease Week® 2016
Janssen Submits Application to U.S. FDA Seeking Approval of a Mebendazole Chewable Tablet for the Treatment of Soil-Transmitted Helminthiasis
Chewable formulation of mebendazole will address an unmet need in treating intestinal worms in young children
Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
Recommendation based on RESONATE™-2 trial which showed IMBRUVICA significantly improved progression-free survival and prolonged overall survival versus chlorambucil